Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jan;37(1):e3350.
doi: 10.1002/dmrr.3350. Epub 2020 Jun 23.

Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis

Richard Ofori-Asenso  1   2 , Berhe W Sahle  3 , Ken Lee Chin  2   4 , Mohsen Mazidi  5 , Zanfina Ademi  2 , Marie Louise De Bruin  1 , Danny Liew  2
Affiliations
Meta-Analysis

Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis

Richard Ofori-Asenso et al. Diabetes Metab Res Rev. 2021 Jan.

Abstract

Aims: Despite increasing prescription of sodium glucose co-transporter 2 (SGLT2) inhibitors, there is limited insight of the patterns of use among patients with diabetes prescribed these drugs. This study aimed to summarize available real-world data on the adherence and persistence to SGLT2 inhibitors.

Materials and methods: A systematic review for observational studies reporting the adherence and persistence to SGLT2 inhibitors was performed in Medline, Embase, and Web of Science from their inception to October 2019. Data were analysed via random-effects meta-analysis.

Results: A total of 22 studies (31 cohorts) comprising 123 854 individuals prescribed SGLT2 inhibitors from eight countries were included. The pooled mean proportions of days covered [PDC] at six months and one year were 0.77 (95% confidence interval [CI] 0.72-0.82) and 0.72 (95% CI 0.66-0.77), respectively. The pooled proportions adherent (PDC ≥0.80) at six months and one year were 59.5% (95% CI 52.9-65.9) and 49.0% (95% CI 42.3-55.8), respectively. The pooled proportions of people persistent at six months, one year, and two years were 80.1% (95% CI 75.8-84.0), 61.8% (95% CI 57.8-65.7), and 45.9% (95% CI 35.5-56.5), respectively. When persistence was defined as the absence of ≥90-days gap, the equivalent pooled proportions persistent were 81.5% (95% CI 73.1-88.6), 58.9% (95% CI 53.1-64.6), and 34.7% (95% CI 33.6-35.8). Adherence and persistence appeared to vary across different SGLT2 inhibitors.

Conclusions: Real-world adherence and persistence to SGLT2 inhibitors is poor. Hence, targets for improving treatment adherence and persistence need to be identified and appropriate interventions implemented.

Keywords: SGLT2; adherence, persistence, discontinuation; sodium glucose cotransporter 2 inhibitors.

PubMed Disclaimer

References

REFERENCES

    1. International Diabetes Federation. Diabetes Facts & Figures: IDF; 2019 Available from: https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html.
    1. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26(2):77-82.
    1. Beckman Joshua A, Creager MA. Vascular complications of diabetes. Circ Res. 2016;118(11):1771-1785.
    1. Davies MJ, D'Alessio DA, Fradkin J, et al. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669.
    1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm-2019 executive summary. Endocr Pract. 2019;25(1):69-100.

MeSH terms

Substances

LinkOut - more resources